Linezolid-Associated Hypoglycemia

ZYVOX® (linezolid) injection, tablets and oral suspension [package insert on the Internet]. New York (NY): Pharmacia and Upjohn Company LLC, Division of Pfizer Inc; 2000 [revised 2017 Jan; cited 2017 Sep 26]. http://labeling.pfizer.com/ShowLabeling.aspx?id=649 .

Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27(8):1189–97.

Vazquez JA, Arnold AC, Swanson RN, Biswas P, Bassetti M. Safety of long-term use of linezolid: results of an open-label study. Ther Clin Risk Manag. 2016;12:1347–54.

Cooper AJ, Ashcroft G. Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs. Lancet. 1966;1(7434):407–9.

Adnitt PI. Hypoglycemic action of monoamineoxidase inhibitors (MAOI’S). Diabetes. 1968;17(10):628–33.

Viswanathan P, Iarikov D, Wassel R, Davidson A, Nambiar S. Hypoglycemia in patients treated with linezolid. Clin Infect Dis. 2014;59(8):e93–5.

Bodnar T, Starr K, Halter JB. Linezolid-associated hypoglycemia in a 64-year-old man with type 2 diabetes. Am J Geriatr Pharmacother. 2011;9(1):88–92.

Johnson PC, Vaduganathan M, Phillips KM, O’Donnell WJ. A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis. Proc (Bayl Univ Med Cent). 2015;28(4):466–8.

American Diabetes Association. 5. Glycemic targets. Diabetes Care. 2016;39(Suppl 1):S39–46.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.

Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.

Nanoukon C, Argemi X, Sogbo F, Orekan J, Keller D, Affolabi D, et al. Pathogenic features of clinically significant coagulase-negative staphylococci in hospital and community infections in Benin. Int J Med Microbiol. 2017;307(1):75–82.

Ozturkeri H, Kocabeyoglu O, Yergok YZ, Kosan E, Yenen OS, Keskin K. Distribution of coagulase-negative staphylococci, including the newly described species Staphylococcus schleiferi, in nosocomial and community acquired urinary tract infections. Eur J Clin Microbiol Infect Dis. 1994;13(12):1076–9.

Hashmi A, Abdullah FE, Abdullah NE, Kazmi SU. Species identification and antibiotic susceptibilities of coagulase- negative staphylococci isolated from urinary tract infection specimens. J Coll Physicians Surg Pak. 2016;26(7):581–4.

Bitew A, Molalign T, Chanie M. Species distribution and antibiotic susceptibility profile of bacterial uropathogens among patients complaining urinary tract infections. BMC Infect Dis. 2017;17(1):654.

Nicolle LE, Hoban SA, Harding GK. Characterization of coagulase-negative staphylococci from urinary tract specimens. J Clin Microbiol. 1983;17(2):267–71.

Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013;173(1):62–8.

Sivextro® (tedizolid) injection [package insert on the Internet]. Whitby (ON): Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2014 [revised 2017 Aug; cited 2017 Oct 9]. https://www.merck.com/product/usa/pi_circulars/s/sivextro/sivextro_pi.pdf .

Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559–69.

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696–705.

Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013;57(7):3060–6.